Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A pill for vitiligo could be on the horizon. Ritlecitinib, an oral JAK/TEC inhibitor already approved for alopecia, hit all efficacy endpoints in two large phase 3 trials involving 1,600+ patients. Responses kept climbing through 52 weeks with no plateau — and if approved, it would be the first-ever oral treatment for vitiligo.
A pill for vitiligo could be on the horizon. Ritlecitinib, an oral JAK/TEC kinase inhibitor already approved for alopecia, met all co-primary efficacy endpoints at week 24 in two global phase 3 trials (TRANQUILLO Part 1a and TRANQUILLO), collectively enrolling over 1,600 patients with moderate-to-severe vitiligo. Crucially, responses kept climbing through week 52 with no sign of plateauing — a promising sign for a condition that typically responds slowly to treatment.
Currently, the only JAK inhibitor approved for vitiligo is ruxolitinib — a topical agent. If approved, ritlecitinib would be the first oral therapy of any kind for vitiligo, potentially offering a meaningful advantage for patients with widespread or actively spreading disease. The safety profile was consistent with prior ritlecitinib studies, with no new signals for malignancy, cardiovascular events, or opportunistic infections.
By the Numbers
Why it matters: Vitiligo has very few effective systemic treatment options. An oral therapy that continues to improve outcomes beyond 24 weeks — especially for patients with extensive disease — could meaningfully shift the treatment landscape.
